Cue Biopharma to Host Business Update Call and Webcast
2024-04-02
免疫疗法
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.
Webcast Details
Monday, April 8 at 4:30 p.m. EDT Investors:1-888-886-7786International Investors:1-416-764-8658Conference ID:02444369Request a return call via the Call me™ link:https://emportal.ink/43Ad9Fs Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time.Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1663846&tp_key=a8d4c834fe
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X (Twitter) and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
jpappas@lifescicomms.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。